← Human Trials & Peer-Reviewed Studies
Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial
Plain-language guide to PMID 17980248 (2007): double-blind randomized controlled trial study of BNP (Nesiritide).
Key Facts
- PMID
- 17980248
- Journal
- Journal of the American College of Cardiology
- Year
- 2007
- Study type
- Randomized Controlled Trial
- Authors
- Witteles RM et al. (7 authors)
- DOI
- 10.1016/j.jacc.2007.03.071
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of BNP (Nesiritide), published as a randomized controlled trial.
Their purpose was to evaluate the impact of nesiritide on renal function in patients with acute decompensated heart failure and baseline renal dysfunction.
Why It Was Studied
Although nesiritide is approved for the treatment of acute decompensated heart failure, retrospective analyses have raised concerns that it may cause worsened renal function.
To date, no randomized clinical trials have prospectively evaluated this issue.
Who Took Part
By PubMed's age tags, the people studied were older adults, both men and women.
Consecutive patients with acute decompensated heart failure and baseline renal dysfunction were enrolled in this randomized, double-blind, placebo-controlled clinical trial.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got BNP (Nesiritide) and who got the comparison, which limits bias.
Blinding on both sides kept the participants and researchers unaware of who received BNP (Nesiritide).
Some participants received a placebo instead of BNP (Nesiritide), giving a reference point.
What Was Measured
To date, no randomized clinical trials have prospectively evaluated this issue.
Topics PubMed links to this paper include Acute Kidney Injury, Creatinine, Heart Failure, Kidney Function Tests and Natriuretic Peptide, Brain.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of BNP (Nesiritide).
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2007 (Journal of the American College of Cardiology), a journal based in United States.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.